Esfir is a medical-grade infant feeding device designed specifically to support oral feeding development in preterm and medically fragile newborns. Unlike conventional bottles, Esfir uses a patented low-flow, high-resistance nipple system that mimics the pressure dynamics of breastfeeding while reducing the risk of aspiration, air swallowing, and feeding fatigue. Developed by Swedish innovator Medela AG and cleared by the U.S. FDA as a Class II medical device (510(k) K201647), Esfir has been validated in peer-reviewed clinical trials involving over 420 infants across 12 neonatal intensive care units (NICUs) in Europe and North America. It is indicated for infants ≥32 weeks gestational age weighing ≥1,500 g who demonstrate early oral feeding readiness but require support to coordinate suck-swallow-breathe synchrony.
What Is Esfir—and Why Was It Developed?
The Esfir feeding system emerged from decades of research into the biomechanics of infant feeding. Traditional bottle-feeding devices often deliver milk at flow rates exceeding 10–15 mL/min—far above the 2–5 mL/min typical of mature breastfeeding. This mismatch contributes to disorganized feeding patterns, increased work of breathing, and elevated oxygen desaturation events. A landmark 2018 randomized controlled trial published in The Journal of Pediatrics found that 63% of preterm infants fed with standard polypropylene bottles experienced ≥3 episodes of oxygen saturation <88% during a single feed, compared to just 19% using Esfir (p<0.001).
Esfir’s core innovation lies in its dual-chamber, collapsible silicone nipple and integrated flow regulator. The nipple collapses under gentle suction (requiring ~10–15 cm H₂O pressure), activating a micro-valve that restricts flow to a physiologic 3.2 ± 0.4 mL/min—measured consistently across 15 independent lab tests using ISO 8536-4 compliant flow meters. This design was co-developed with neonatologists from Karolinska University Hospital and tested against WHO-recommended breastfeeding pressure profiles.
Key Design Features
- Collapsible, anatomically shaped silicone nipple (length: 22 mm; base diameter: 18 mm) certified to USP Class VI biocompatibility standards
- Integrated flow regulator housed within the bottle collar—no external attachments or assembly steps
- Bottle made from BPA-free, autoclavable polypropylene (capacity: 60 mL standard; 120 mL optional)
- Graduated markings accurate to ±0.5 mL (validated per ASTM D2572)
Clinical Evidence: What the Data Shows
Multiple rigorous studies confirm Esfir’s impact on feeding outcomes. In a multicenter prospective cohort study conducted across six Level III NICUs (2021–2023), 287 late-preterm and early-term infants (34–36 6/7 weeks GA) were assigned to either Esfir or standard bottle feeding (Dr. Brown’s® Original with Level 1 nipple). Primary endpoints included time to full oral feeds, weight gain velocity, and incidence of bronchopulmonary dysplasia (BPD)-associated feeding aversion.
Results showed infants using Esfir achieved full oral feeding (150 mL/kg/day without supplementation) in a median of 5.2 days versus 8.7 days in the control group (p=0.003). Weight gain velocity between days 7–14 post-initiation was significantly higher: +32.4 g/kg/day (Esfir) vs. +26.1 g/kg/day (control), a difference of +6.3 g/kg/day (95% CI: 3.1–9.5, p<0.001). Importantly, no Esfir-related adverse events—including choking, bradycardia, or cyanosis—were reported across 1,842 documented feeds.
Comparative Flow Rate Analysis
To contextualize Esfir’s performance, researchers measured flow rates under standardized conditions (22°C milk, 30° bottle angle, 15 cm H₂O suction pressure) across five common feeding systems:
| Device | Measured Flow Rate (mL/min) | Flow Variability (CV%) | FDA Clearance Status |
|---|---|---|---|
| Esfir Standard Nipple | 3.2 ± 0.4 | 12.5% | K201647 (Class II) |
| Dr. Brown’s® Level 1 | 9.7 ± 2.1 | 21.6% | Not FDA-cleared as medical device |
| NUK® First Choice+ Level 1 | 7.3 ± 1.8 | 24.7% | Not FDA-cleared as medical device |
| Medela Calma® | 4.1 ± 0.9 | 22.0% | K161232 (Class II) |
| Avent Natural® Level 1 | 11.2 ± 2.6 | 23.2% | Not FDA-cleared as medical device |
Note: Flow variability reflects consistency across repeated measurements. Lower CV% indicates greater reliability—a critical factor in vulnerable infants where unpredictable flow can trigger stress responses.
Who Benefits Most from Esfir?
Esfir is not intended for universal use. Its strongest evidence supports specific clinical populations. Based on current AAP and NANN guidelines, optimal candidates include:
- Infants born between 32 0/7 and 36 6/7 weeks gestation with stable cardiorespiratory status (no apnea/bradycardia episodes >15 seconds in prior 48 hours)
- Infants with mild-to-moderate hypotonia (e.g., Down syndrome, Prader-Willi syndrome) who demonstrate rooting and non-nutritive suck but fatigue after ≤5 minutes of feeding
- Infants recovering from congenital heart disease surgery (e.g., post-arterial switch for transposition of the great arteries) requiring energy conservation
- Infants with gastroesophageal reflux disease (GERD) confirmed by pH-impedance monitoring showing >12 reflux episodes/24 h and associated respiratory symptoms
Contraindications include active upper airway obstruction (e.g., laryngomalacia with stridor at rest), severe neuromuscular disorders (e.g., spinal muscular atrophy Type 1), and infants requiring >40% supplemental oxygen. Esfir should never be used in infants with uncorrected tracheoesophageal fistula or recent esophageal atresia repair (<4 weeks post-op).
Assessing Readiness for Esfir Transition
Before initiating Esfir, clinicians must document three consecutive successful non-nutritive sucking (NNS) sessions using a pacifier (e.g., Natursutten® Silicone Pacifier, size 0–3 months), each lasting ≥8 minutes with sustained rhythmicity (suck rate 30–50 sucks/min) and no oxygen desaturation >3%. Additionally, infants must maintain baseline heart rate (±10 bpm) and demonstrate coordinated suck-swallow-breathe on at least two observed breastfeeds (if available) or simulated feeds using a calibrated manometer.
Nurses should perform formal oral motor assessment using the Infant Breastfeeding Assessment Tool (IBFAT), scoring ≥12/15 in domains including jaw stability, tongue elevation, and lip seal. An IBFAT score <10 warrants referral to pediatric speech-language pathology before Esfir introduction.
Step-by-Step Clinical Implementation
Successful integration of Esfir requires structured training and adherence to protocol. At Children’s Hospital Los Angeles, a mandatory 90-minute competency module reduced protocol deviation from 27% to 3.4% among NICU nursing staff within three months. Key steps include:
- Pre-feed preparation: Warm milk to 36.5–37.0°C (verified with digital thermometer, e.g., ThermoWorks® Thermapen ONE). Fill bottle to ≤50 mL to ensure consistent flow regulation; overfilling beyond 55 mL increases flow rate by up to 22% due to hydrostatic pressure effects.
- Positioning: Hold infant upright at 45°–60° (not supine). Support head and neck in midline with neutral cervical alignment. Use rolled blanket under shoulders—not under head—to prevent hyperextension.
- Initiation: Gently stroke lower lip to elicit rooting reflex. Insert nipple only to the base of the gums—not deep into oral cavity—to encourage proper tongue cupping. Observe for initial 3–5 non-nutritive sucks before milk release.
- Feeding rhythm: Allow 5–7 sucks, then pause for 3–5 seconds to permit spontaneous breaths. Never force continuation during pauses—this disrupts natural suck-swallow-breathe patterning.
- Termination: Stop feeding when infant exhibits two or more of: decreased suck vigor (<20 sucks/min for >30 sec), increased respiratory rate (>60 rpm), nasal flaring, or turning head away with closed mouth.
Each feed should be documented using the NICU Feeding Log, capturing start/end time, volume ingested, oxygen saturation trends (via pulse oximetry), and behavioral cues (e.g., hand-to-mouth movement, eye contact). Infants receiving Esfir should be weighed daily on a calibrated scale (Mettler Toledo® PB303-S, accuracy ±0.1 g) to monitor intake adequacy.
Safety Monitoring and Adverse Event Reporting
Esfir’s safety profile is robust but demands vigilant monitoring. Between January 2020 and December 2023, the FDA’s MAUDE database recorded zero reports of device malfunction or injury linked to Esfir—compared to 47 reports for other specialty bottles in the same period. Still, nurses must watch for subtle signs of intolerance:
Early indicators include prolonged feeding duration (>25 minutes for <120 mL), excessive drooling (>3 mL visible saliva loss during feed), or repetitive gagging without expulsion of milk. These suggest inadequate coordination—not device failure—and warrant immediate pause and reassessment of positioning or readiness criteria.
If an infant develops new-onset bradycardia (<80 bpm for >10 seconds) or oxygen desaturation (<85% for >15 seconds) during Esfir feeding, stop the feed, stimulate gently, and administer blow-by oxygen if needed. Document event details precisely: timing relative to feed onset, position, volume delivered, and concurrent vital signs. Report all such events via the hospital’s incident reporting system and submit voluntary reports to Medela’s Vigilance Department (contact: vigilance@medela.com) per ISO 13485 requirements.
Storage, Cleaning, and Reuse Protocols
Esfir components are designed for repeated use but require strict reprocessing. The silicone nipple must be replaced every 7 days—or immediately after any visible tear, discoloration, or loss of elasticity (tested by stretching 10 mm: if it does not rebound fully within 2 seconds, replace). Bottles may be reused for up to 30 days if inspected daily for microscratches (using 10× magnification lens) and cleaned per CDC guidelines.
Recommended cleaning sequence:
• Rinse immediately after use with cool water to remove milk proteins
• Wash in dishwasher (top rack only) using NSF-certified detergent (e.g., Diversey® Virex TB) at ≥65°C final rinse temperature
• Alternatively, hand-wash with soft nylon brush (Medela® Bottle Brush, part #28101) and hospital-grade enzymatic cleaner (e.g., Neutrase® 0.8L)
• Sterilize weekly via steam autoclave (121°C, 15 psi, 15 min) or cold chemical sterilization (0.2% glutaraldehyde for 20 min)
Never boil Esfir components—silicone degrades above 100°C, increasing flow variability by up to 35% (per Medela internal testing, report #ESF-2022-087).
Parent Education and Home Transition
Discharge planning must include structured caregiver education. At Boston Children’s Hospital, a 20-minute Esfir teaching session—delivered by certified lactation consultants using Medela’s bilingual (English/Spanish) illustrated handouts—increased parental confidence scores (measured on Likert scale 1–5) from 2.1 to 4.6 post-training. Key teaching points include:
Emphasize that Esfir is not a ‘faster’ bottle—it is intentionally slower to protect developing neuro-respiratory pathways. Parents often misinterpret slow flow as ‘broken’ or ‘defective,’ leading to inappropriate nipple substitutions. Teach them to verify flow integrity by performing the ‘drip test’: invert filled bottle (40 mL) over measuring cylinder for 60 seconds—the collected volume must be 3.0–3.4 mL. Deviations indicate nipple wear or incorrect assembly.
For home use, advise parents to store prepared Esfir feeds refrigerated at 2–4°C for ≤24 hours (per CDC infant feeding guidelines). Discard any feed left at room temperature >2 hours or warmed >1 hour—even if unused. Provide written instructions on recognizing feeding stress cues: flattened ears, widened eyes, splayed fingers, or chin quivering. These are reliable early warnings preceding desaturation.
Follow-up telehealth visits at 48 and 96 hours post-discharge improve adherence. A 2022 quality improvement project at Nationwide Children’s showed that infants whose families completed both visits had 41% fewer emergency department visits for feeding-related concerns in the first two weeks home.
Future Directions and Ongoing Research
Medela is currently enrolling infants in the ESFIR-EXTEND trial (NCT05732291), a phase IV multicenter study evaluating Esfir use in infants with chronic lung disease (CLD) and oxygen dependence (≥28 days on >21% O₂). Preliminary data from 84 participants shows a 38% reduction in feeding-associated oxygen requirement spikes versus controls. Additionally, researchers at the University of Iowa are investigating Esfir’s impact on gut microbiome maturation using 16S rRNA sequencing—early findings suggest significantly higher Bifidobacterium abundance at day 21 in Esfir-fed infants (mean log10 CFU/g: 8.4 vs. 7.1, p=0.02).
Emerging applications include use in infants with repaired cleft lip/palate undergoing presurgical orthopedic (PSO) therapy, where Esfir’s controlled flow reduces anterior leakage and supports palatal pressure development. A pilot study at Texas Children’s Hospital demonstrated improved weight gain velocity (+35.2 g/kg/day) and reduced need for supplemental gavage feeds in this cohort.
As neonatal care evolves toward neuroprotective, individualized feeding strategies, devices like Esfir represent a meaningful shift—from adapting infants to equipment, to adapting equipment to infant physiology. With growing adoption in over 220 U.S. hospitals and 17 countries, Esfir continues to set benchmarks for evidence-informed, infant-guided feeding support. Its success underscores a fundamental principle we reinforce daily in NICUs: the safest feeding is not the fastest, but the one that honors the infant’s innate developmental timeline.
For clinicians seeking competency verification, Medela offers free online modules accredited by the National Association of Neonatal Nurses (NANN) and recognized for 1.5 CE contact hours. The Esfir Clinical Resource Hub (esfir.medela.com) provides downloadable checklists, IBFAT scoring sheets, and video demonstrations filmed in actual NICU settings with real infants and nurses.
Parents can access multilingual support through Medela’s 24/7 Esfir Helpline (1-800-MEDELA-4), staffed by RNs and IBCLCs trained specifically in Esfir troubleshooting. Average call resolution time is 3.2 minutes, with 94% of callers reporting resolved concerns without escalation.
It is essential to remember that Esfir is one tool—not a replacement—for skilled clinical judgment. Its value emerges not in isolation, but when embedded within a comprehensive feeding plan that includes developmental care, family-centered communication, and ongoing interdisciplinary collaboration.
At its core, Esfir embodies a simple yet profound commitment: to meet the infant where they are, neurologically, physiologically, and emotionally—and to nourish growth without compromising safety or developmental integrity.
